Spyre Therapeutics, Inc.
90.33USD
-2.0000 (-2.17%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SYRE.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.84▼ | -$0.73 | 2 | 8 |
| Next quarter | -$0.88▼ | -$0.69 | 3 | 9 |
| Current year | -$2.83▲ | -$2.95 | 9 | 3 |
| Next year | -$3.51▼ | -$3.13 | 3 | 8 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.75 | -$0.36 | +0.39 (+51.8%) |
| 2026-03-31 | -$0.65 | -$0.74 | -0.09 (-13.1%) |
| 2025-12-31 | -$0.8 | -$0.74 | +0.06 (+7.2%) |
| 2025-09-30 | -$0.74 | -$0.15 | +0.59 (+79.7%) |
56 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| BTIG | Reiterated | Buy | $121 | Oct 19, 2026 |
| UBS | Initiated | Buy | $120 | Oct 12, 2026 |
| JP Morgan | Initiated | Overweight | $110 | Oct 1, 2026 |
| BTIG | Reiterated | Buy | $121 | Oct 1, 2026 |
| Wedbush | Reiterated | Outperform | $123 | Sep 9, 2026 |
| BTIG | Reiterated | Buy | $121 | Sep 8, 2026 |
| Deutsche Bank | Maintained | Buy | $135 $127 | Aug 26, 2026 |
| Wedbush | Maintained | Outperform | $130 $123 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $132 $121 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $112 $132 | Aug 11, 2026 |
| Wells Fargo | Maintained | Overweight | $90 $115 | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $115 $130 | Aug 5, 2026 |
| Wedbush | Maintained | Outperform | $100 $130 | Aug 5, 2026 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $84 $120 | Jul 13, 2026 |
| Deutsche Bank | Maintained | Buy | $115 $135 | Jun 23, 2026 |
| BTIG | Maintained | Buy | $98 $112 | Jun 15, 2026 |
| Deutsche Bank | Maintained | Buy | $102 $115 | Jun 4, 2026 |
| Citigroup | Maintained | Buy | $64 $97 | May 6, 2026 |
| Stifel | Maintained | Buy | $92 $107 | May 6, 2026 |
| Jones Trading | Maintained | Buy | $64 $95 | Apr 17, 2026 |
| Wells Fargo | Maintained | Overweight | $50 $90 | Apr 14, 2026 |
| Wedbush | Maintained | Outperform | $65 $80 | Apr 14, 2026 |
| Baird | Maintained | Outperform | $65 $90 | Apr 14, 2026 |
| Raymond James | Initiated | Strong Buy | $80 | Apr 14, 2026 |
85 filings from 9 insiders · 12 buy / 19 sell over 6m
Officers and directors of SYRE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Burrows Scott LOfficer, Chief Financial Officer | Exercise | 7.5k | $14.50 | $109k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 600 | $89.07 | $53k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 1.5k | $90.27 | $135k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 2.1k | $91.92 | $193k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 3.1k | $92.95 | $285k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | Sell | 229 | $93.57 | $21k | Oct 1, 2026 |
| Burrows Scott LOfficer, Chief Financial Officer | ExerciseStock Option (Right to Buy) | 7.5k | — | — | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 600 | $89.14 | $53k | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 2.7k | $90.10 | $242k | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 2.6k | $91.49 | $241k | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 4.0k | $92.31 | $368k | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 5.0k | $93.37 | $466k | Oct 1, 2026 |
| Turtle CameronDirector; Officer, Chief Executive Officer | Sell | 100 | $93.91 | $9k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Exercise | 28.9k | $14.50 | $420k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 400 | $89.24 | $36k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 16.6k | $90.35 | $1.50M | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 7.2k | $91.35 | $660k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 2.1k | $92.70 | $195k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | Sell | 2.6k | $93.46 | $243k | Oct 1, 2026 |
| King-Jones HeidyOfficer, See Remarks | ExerciseStock Option (Right to Buy) | 28.9k | — | — | Oct 1, 2026 |
No analyst notes on SYRE yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 16 | 1 | 0 | 0 | Buy2.00 |
| 1 mo ago | 0 | 15 | 1 | 0 | 0 | Buy2.06 |
| 2 mo ago | 0 | 16 | 1 | 0 | 0 | Buy2.06 |
| 3 mo ago | 0 | 16 | 1 | 0 | 0 | Buy2.06 |
Members whose judged calls on SYRE have played out most reliably.
No settled calls on SYRE yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice